Estrogen and gastrointestinal malignancy.
The concept that E2 exerts an effect on the gastrointestinal tract is not new and its actions on intestinal mucosa have been investigated for at least three decades. An attempt to consolidate results of these investigations generates more questions than answers, thus suggesting that many unexplored avenues remain and that the full capabilities of this steroid hormone are far from understood. Evidence of its role in esophageal, gastric and gallbladder cancers is confusing and often equivocal. The most compelling evidence regards the protective role conferred by estrogen (or perhaps ERbeta) against the development and proliferation of colon cancer. Not only has the effect been described but also many mechanisms of action have been explored. It is likely that, along with surgery, chemotherapy and radiotherapy, hormonal manipulation will play an integral role in colon cancer management in the very near future.
Hogan
A M
AM
Institute for Clinical Outcomes Research and Education (iCORE), St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Aislinghogan@yahoo.com
Collins
D
D
Baird
A W
AW
Winter
D C
DC
D003110:Colonic Neoplasms / Q000378:metabolism; D004938:Esophageal Neoplasms / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism*; D005706:Gallbladder Neoplasms / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000378:metabolism*; D006801:Humans; D013274:Stomach Neoplasms / Q000378:metabolism
D004967:Estrogens